Patents by Inventor Wylie Vale
Wylie Vale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9546210Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: GrantFiled: September 21, 2010Date of Patent: January 17, 2017Assignee: Research Development FoundationInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Patent number: 9314506Abstract: Methods and compositions are provided for stimulating insulin production, increasing beta cell mass, or decreasing beta cell loss in a subject. For example, methods of the embodiments can comprise administration of a corticotropin-releasing factor (CRF)1 receptor agonist and a CRF2 receptor agonist. Also provided are pharmaceutical compositions comprising a selective CRF1 receptor agonist and a selective CRF2 receptor agonist.Type: GrantFiled: October 24, 2012Date of Patent: April 19, 2016Assignee: Research Development FoundationInventors: Mark Huising, Masahito Matsumoto, Wylie Vale
-
Patent number: 8258279Abstract: The present invention is directed to compositions and methods related to soluble G-protein coupled receptors (sGPCR). In certain aspects the invention includes compositions and methods related to a soluble corticotropin releasing factor receptor related protein, sCRFR2, as well as its effects on CRFR signaling and interaction between CRF family ligand and CRFR receptors, including but not limited to CRFR2, CRFR1 and functional or signaling capable variants thereof.Type: GrantFiled: September 24, 2008Date of Patent: September 4, 2012Assignee: Research Development FoundationInventors: Alon Chen, Marilyn Perrin, Wylie Vale
-
Publication number: 20120141469Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: ApplicationFiled: October 19, 2011Publication date: June 7, 2012Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Publication number: 20120088287Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: ApplicationFiled: October 19, 2011Publication date: April 12, 2012Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Publication number: 20110009319Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: ApplicationFiled: September 21, 2010Publication date: January 13, 2011Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Patent number: 7820620Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: GrantFiled: September 14, 2004Date of Patent: October 26, 2010Assignee: Research Development FoundationInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Publication number: 20100135904Abstract: The present invention provides methods compositions and methods for treating a hyperproliferative disease comprising disrupting Cripto/GRP78 complex formation in a hyperproliferative cell. In certain embodiments, an antibody and/or siRNA may be used to inhibit Cripto/GRP78 binding, optionally coupled with other cancer therapies. Also provided are methods for identifying therapeutic compounds which can selectively inhibit Cripto/GRP78 binding.Type: ApplicationFiled: November 9, 2009Publication date: June 3, 2010Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Peter C. Gray, Gidi Shani, Jonathan A. Kelber, Wylie Vale
-
Patent number: 7575751Abstract: Members of the TGF-? superfamily control many physiologic and pathophysiologic processes in multiple tissues and signal via type II and type I receptor serine kinases. Type II activin receptors are promiscuous and known to bind 12 TGF-? ligands including activins, myostatin, BMPs and nodal. Methods are described for the screening and identification of antagonist for TGF-? superfamily members, in particular activin-A antagonist.Type: GrantFiled: April 27, 2005Date of Patent: August 18, 2009Assignee: Research Development FoundationInventors: Wylie Vale, Craig Harrison, Peter Gray, Wolfgang Fischer, Senyon Choe
-
Publication number: 20090117649Abstract: The present invention is directed to compositions and methods related to soluble G-protein coupled receptors (sGPCR). In certain aspects the invention includes compositions and methods related to a soluble corticotropin releasing factor receptor related protein, sCRFR2, as well as its effects on CRFR signaling and interaction between CRF family ligand and CRFR receptors, including but not limited to CRFR2, CRFR1 and functional or signaling capable variants thereof.Type: ApplicationFiled: September 24, 2008Publication date: May 7, 2009Inventors: ALON CHEN, MARILYN PERRIN, WYLIE VALE
-
Patent number: 7507794Abstract: The present invention is directed to compositions and methods related to soluble G-protein coupled receptors (sGPCR). In ceratin aspects the invention includes compositions and methods related to a soluble corticotropin releasing factor receptor related protein, sCRFR2, as well as its effects on CRFR signaling and interaction between CRF family ligand and CRFR receptors, including but not limited to CRFR2, CRFR1 and functional or signaling capable variants thereof.Type: GrantFiled: February 8, 2006Date of Patent: March 24, 2009Assignee: Research Development FoundationInventors: Alon Chen, Marilyn Perrin, Wylie Vale
-
Patent number: 7488865Abstract: The present invention provides transgenic mice deficient in urocortin. Urocortin null mutant mice are hypersensitive to stress and display heightened anxiety-like behaviors in the elevated plus maze and open field tests. These mice also demonstrate physiological alterations in auditory thresholds and distortion product otoacoustic emissions. These results indicate that urocortin plays a modulatory role in anxiety-related behaviors and in contributing to the establishment of auditory thresholds. Such urocortin deficient mutant mice can provide useful models in the study of anxiety pathology and hearing physiology at the biochemical and molecular levels.Type: GrantFiled: May 19, 2003Date of Patent: February 10, 2009Assignee: Research Development FoundationInventors: Kuo-Fen Lee, Wylie Vale, Chien Li, Lingyun Zhao, Douglas E. Vetter
-
Patent number: 7455839Abstract: Inhibins and activins are protein hormones that reciprocally modulate a diversity of regulatory pathways. Competitive binding experiments revealed that betaglycan, the type III TGF-? receptor, also functions as an inhibin receptor. Betaglycan augments the binding of inhibin to the ActRII activin receptor. By augmenting inhibin binding to ActRII, betaglycan effectively sequesters ActRII away from activin and thereby reduces activin signaling. In addition, the ActRII-betaglycan complex may generate novel signals distinct from those initiated by activin signaling via ActRII and ALK4. Betaglycan is produced in discrete nuclei of the rat brain and by specific cell types within the adult rat pituitary, testis, and ovary. The presence of betaglycan within inhibin-responsive tissues and cell types, together with the ability of this protoglycan to bind inhibin and to confer inhibin sensitivity, is consistent with a role of betaglycan as an inhibin-specific receptor mediating inhibin responses within various tissues.Type: GrantFiled: October 29, 2003Date of Patent: November 25, 2008Assignee: Research Development FoundationInventors: Wylie Vale, Kathy A. Lewis, Peter C. Gray, Louise M. Bilezikjian, Amy L. Blount
-
Publication number: 20070191592Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse CDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.Type: ApplicationFiled: April 5, 2007Publication date: August 16, 2007Applicant: Research Development FoundationInventors: Wylie Vale, Teresa Reyes, Paul Sawchenko, Jean Rivier, Kathy Lewis, John Hogenesch, Joan Vaughan, Marilyn Perrin
-
Publication number: 20070042954Abstract: The present invention is directed to compositions and methods related to soluble G-protein coupled receptors (sGPCR). In ceratin aspects the invention includes compositions and methods related to a soluble corticotropin releasing factor receptor related protein, sCRFR2, as well as its effects on CRFR signaling and interaction between CRF family ligand and CRFR receptors, including but not limited to CRFR2, CRFR1 and functional or signaling capable variants thereof.Type: ApplicationFiled: February 8, 2006Publication date: February 22, 2007Inventors: Alon Chen, Marilyn Perrin, Wylie Vale
-
Publication number: 20060069516Abstract: The present invention relates to a method for identifying modulators of B1 G-protein coupled receptors. The present invention also relates to a method for identifying an antagonist or agonist of the corticotropin-releasing factor receptor 2 (CRFR2). The present invention also relates to a method for improving antagonists or agonists of CRFR2. The present invention also relates to the three-dimensional structure of CRFR2 as representative of the B1 GPCR subfamily and its use as a basis for rational drug design of antagonist or agonists of B1 GPCRs.Type: ApplicationFiled: August 9, 2005Publication date: March 30, 2006Applicant: Research Development FoundationInventors: Grace Royappa, Marilyn Perrin, Jean Rivier, Wylie Vale, Roland Riek
-
Publication number: 20060008846Abstract: Members of the TGF-? superfamily control many physiologic and pathophysiologic processes in multiple tissues and signal via type II and type I receptor serine kinases. Type II activin receptors are promiscuous and known to bind 12 TGF-? ligands including activins, myostatin, BMPs and nodal. Methods are described for the screening and identification of antagonist for TGF-? superfamily members, in particular activin-A antagonist.Type: ApplicationFiled: April 27, 2005Publication date: January 12, 2006Inventors: Wylie Vale, Craig Harrison, Peter Gray, Wolfgang Fischer, Senyon Choe
-
Publication number: 20060003937Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.Type: ApplicationFiled: August 29, 2005Publication date: January 5, 2006Inventors: Wylie Vale, Kathy Lewis, Marilyn Perrin, Koichi Kunitake, Jean Rivier, Jozsef Gulyas
-
Publication number: 20050208045Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b.type II.type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: ApplicationFiled: September 14, 2004Publication date: September 22, 2005Inventors: Wylie Vale, Craig Harrison, Peter Gray
-
Publication number: 20050191650Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn II. Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.Type: ApplicationFiled: October 25, 2004Publication date: September 1, 2005Applicant: Neurocrine Biosciences, Inc.Inventors: Wylie Vale, Teresa Reyes, Paul Sawchenko, Jean Rivier, Kathy Lewis, John Hogenesch, Joan Vaughan, Marilyn Perrin